Daiichi Sankyo Company, Limited announced that it has obtained approval in Japan to change the indication of the analgesic “Tarlige tablets” (mirogabalin besilate) from “peripheral neuropathic pain” to “neuropathic pain.”
Singapore-based Menarini Asia-Pacific Holdings, a part of the leading Italian global biopharmaceutical company Menarini Group, has signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (brand name; TARLIGE®), in the Philippines, Malaysia and Singapore.
TOKYO, Japan (December 18, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the achievement of the primary endpoint of phase 3 study (hereinafter, Study) mirogabalin for central neuropathic pain after spinal cord injury.
TOKYO, Japan (December 18, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the achievement of the primary endpoint of phase 3 study (hereinafter, Study) mirogabalin for central neuropathic pain after spinal cord injury.
Just a few weeks after getting its first approval for neuropathic pain drug mirogabalin, Daiichi Sankyo kicked off a new phase 3 programme to extend its use in patients with spinal cord injuries.